Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for AMEX:INO
-0.19 (-1.84%)
Real-time:   12:44PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.53 - 10.30
52 week 6.33 - 14.20
Open 10.15
Vol / Avg. 600,717.00/1.39M
Mkt cap 599.51M
P/E     -
Div/yield     -
EPS -0.62
Shares 60.74M
Beta 2.79
Inst. own 29%
May 11, 2015
Q1 2015 Inovio Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 16, 2015
Q4 2014 Inovio Pharmaceuticals Inc Earnings Release
Mar 16, 2015
Q4 2014 Inovio Pharmaceuticals Inc Earnings Call - Webcast
Feb 9, 2015
Inovio Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 5, 2015
Inovio Pharmaceuticals Inc at Emerald Research Groundhog Day Investment Forum
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -301.68% -345.61%
Operating margin -448.16% -377.71%
EBITD margin - -362.17%
Return on average assets -22.33% -32.84%
Return on average equity -26.08% -44.14%
Employees 106 -
CDP Score - -


10480 Wateridge Cir
SAN DIEGO, CA 92121-5773
United States - Map
+1-858-5976006 (Phone)
+1-858-4041392 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage biopharmaceutical company. Inovio develops deoxyribonucleic acid (DNA)-based vaccines and immune therapies, called synthetic vaccines, in combination with electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio�s synthetic vaccines are based on the Company�s SynCon vaccine design. The Company has completed, current or planned clinical programs of its SynCon vaccines and immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, malaria and Ebola. The synthetic vaccine platform comprises the Company�s SynCon vaccine design process as well as its electroporation delivery technology. Inovio has developed a pre-clinical and clinical-stage pipeline of products.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Nancy J. Wysenski Director
Age: 57
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 70
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Morton Collins Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters